Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approval of Intragastric Balloon System

Device assists adults with weight management

Indications: The ORBERA Intragastric Balloon System is indicated for adult obese patients who have a body mass index (BMI) of 30 to 40 kg/m2 who have been unable to lose weight through diet and exercise.

Mechanism of action: The temporary system is placed into the stomach through the mouth, helps patients lose weight and should be removed after 6 months.

Efficacy and safety: In a clinical trial, 255 patients who used the system lost an average of 22 pounds. The device should not be used in patients who already have an intragastric balloon, have had prior gastrointestinal or bariatric surgery, or have any inflammatory disease of the GI tract.

Citation: FDA website. ORBERA intragastric balloon system. http://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapp.... Updated August 6, 2015. Accessed August 11, 2015.

This Week's Must Reads

Increased Water Intake in Premenopausal Women with UTIs, JAMA Intern Med; ePub 2018 Oct 1; Hooton, et al

Adverse Childhood Experiences & Weight Status, J Pediatr; ePub 2018 Oct 1; Davis, Barnes, et al

Prevalence of E-Cigarette Use Among US Adults, Ann Intern Med; 2018 Oct 2; Mirbolouk, et al

Continuous Combined Oral Contraceptives & VTE Risk, JAMA Intern Med; ePub 2018 Oct 1; Li, et al

Wearable Cardioverter-Defibrillator Use After MI, N Engl J Med; 2018 Sep 27; Olgin, et al

Must Reads in Obesity

Adverse Childhood Experiences & Weight Status, J Pediatr; ePub 2018 Oct 1; Davis, Barnes, et al

Subjective Wellbeing and Cardiometabolic Health, BMJ; ePub 2018 Sep 25; Wootton, et al

Effect of Fish Oil Supplementation in Pregnancy, BMJ; ePub 2018 Sep 4; Vinding, Stokholm, et al

Smoking Cessation & Body Weight in T2D, N Engl J Med; 2018 Aug 16; Hu, Zong, et al

Long-Term Weight Loss & Metabolic Health, Mayo Clin Proc; ePub 2018 Aug 14; Knell, et al